FDA
An Alternative Point of View: The Societal Benefits of the Amgen v. Regeneron Injunction
By Beau H. Miller This article was originally published as part of research issued by the Jefferies Biotechnology Equity Research group. Since the Amgen v. Regeneron ruling that resulted in Judge Robinson of the District…